Septerna, Inc.

NASDAQ:SEPN

Biotechnology

Healthcare
$39.45 -2.04%

-$0.73 today

Market cap
$1.88B
Beta
2.38
P/E (TTM)
-43.6
EPS (TTM)
-$0.81
52W Low $9.96High $37.32

Volume 0.30M

Average 0.32M

SEPN Other Working Capital

Cash effect of changes in other operating assets and liabilities.

Septerna, Inc.NASDAQ: SEPN

Other Working Capital · Q3 FY2026 · quarter ended Sep 2026

Other working capital declines year over year

Q3 FY2026 other working capital of $33.19M fell 81.7% year over year, ahead of the -106.4% change in trailing-twelve-month other working capital. Over 3 fiscal years it compounded at +1926.2% a year.

Context

  • Other working capital amounted to 362.0% of revenue in FY2025, up 319.7 pp from a year earlier.
  • Other working capital increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -81.7% holds above the trailing-twelve-month pace of -106.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$33.19M+360.7% QoQ
Last fiscal yearDec 2025
$166.36M+36662.4% YoY
LTMSep 2026
-$11.35M-106.4% YoY
Other Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-81.7%——
1 year+36662.4%——
3-year CAGR+1926.2%——
5-year CAGR——
10-year CAGR——

Other Working Capital history

USD · from the cash flow

Latest · FY2025
166.36M USD
Year-over-year change
+36662.4%
3-year CAGR
+1926.2%

Other Working Capital vs competitors

How SEPN compares with its peers on the latest reported figures

  • SEPN's LTM Sep 2026 other working capital of $11.35M is the 4th largest of the 7 companies compared; the peer median is $2.46M.
  • Its year-over-year change of -106.4% is the 5th highest of 6, against a peer median of +9.3%.
  • Other working capital amounts to 11.8% of revenue for SEPN, versus a peer median of 33.1%.
SEPN Competitors Peer median
Other Working Capital for SEPN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GPCRStructure Therapeutics Inc.LTM Jun 2026$44.78M -1818.8%——
VTVTvTv Therapeutics Inc.LTM Mar 2026$16.74M +7946.6%-61.5%45.4%
KLRAKailera Therapeutics, Inc.FY2025$12.09M ———
SEPNSepterna, Inc.LTM Sep 2026$11.35M -106.4%+1926.2%11.8%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$8.6M +2505.8%+86.7%—
MAZEMaze Therapeutics, Inc.LTM Mar 2026$4.17M +9.3%—20.8%
BMEABiomea Fusion, Inc.LTM Mar 2026$743K -92.3%+8.4%—
Peer median (excluding SEPN) $2.46M+9.3%+8.4%33.1%

Competitors are the stored peer set for SEPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(27.68M)4.18M(71.8M)(48.88M)
Depreciation & Amortization577K848K1.4M1.6M
Deferred Income Tax0491K(491K)0
Stock-Based Compensation1.52M1.62M3.15M8.48M
Change in Working Capital1.75M926K248K162.78M
Accounts Receivables0(151K)(20K)(10.19M)
Inventory0000
Accounts Payables1.73M(653K)723K6.6M
Other Working Capital20K1.73M(455K)166.36M
Other Non-Cash Items530K(46.79M)18K(13.79M)
Operating Cash Flow(23.3M)(38.72M)(67.47M)110.19M
Capital Expenditures(1.29M)(2.88M)(2.1M)(518K)
Acquisitions (Net)00012.5M
Purchases of Investments00(213.39M)(450.95M)
Sales of Investments0032.27M209.62M
Other Investing Activities025M22.63M0
Investing Cash Flow(1.29M)22.12M(160.6M)(229.35M)
Debt Repayment0000
Common Stock Issued82K0302.79M1.69M
Common Stock Repurchased0(1K)(1K)(1K)
Dividends Paid0000
Other Financing Activities0052K0
Financing Cash Flow30.05M74.52M377.78M1.69M
Effect of Forex Changes0000
Net Change in Cash5.46M57.92M149.71M(117.47M)
Free Cash Flow(24.59M)(41.6M)(69.57M)109.67M

Septerna, Inc.

NASDAQ:SEPN

Intrinsic Alpha fair value

Locked

Current Price

$39.45

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.